Bank of New York Mellon Corp Acquires 19,005 Shares of Syros Pharmaceuticals Inc (SYRS)

Bank of New York Mellon Corp boosted its position in shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) by 36.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 70,592 shares of the company’s stock after purchasing an additional 19,005 shares during the period. Bank of New York Mellon Corp owned about 0.22% of Syros Pharmaceuticals worth $720,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in SYRS. Schwab Charles Investment Management Inc. lifted its holdings in Syros Pharmaceuticals by 76.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 76,740 shares of the company’s stock valued at $997,000 after purchasing an additional 33,315 shares during the last quarter. Northern Trust Corp lifted its holdings in Syros Pharmaceuticals by 35.0% during the 1st quarter. Northern Trust Corp now owns 181,090 shares of the company’s stock valued at $2,351,000 after purchasing an additional 46,927 shares during the last quarter. BlackRock Inc. lifted its holdings in Syros Pharmaceuticals by 61.7% during the 1st quarter. BlackRock Inc. now owns 929,537 shares of the company’s stock valued at $12,066,000 after purchasing an additional 354,591 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Syros Pharmaceuticals by 13.9% during the 1st quarter. JPMorgan Chase & Co. now owns 374,513 shares of the company’s stock valued at $4,861,000 after purchasing an additional 45,715 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Syros Pharmaceuticals by 299.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after purchasing an additional 9,691 shares during the last quarter. 60.70% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently issued reports on SYRS shares. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a report on Tuesday, July 17th. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, August 10th. BidaskClub downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. Cann reissued a “buy” rating and set a $26.00 price target on shares of Syros Pharmaceuticals in a report on Tuesday, August 7th. Finally, HC Wainwright reissued a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a report on Wednesday, August 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Syros Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $19.29.

Shares of NASDAQ SYRS opened at $7.11 on Friday. Syros Pharmaceuticals Inc has a 1-year low of $6.30 and a 1-year high of $17.50. The stock has a market capitalization of $249.72 million, a price-to-earnings ratio of -3.34 and a beta of -1.96.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Friday, August 10th. The company reported ($0.43) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07. The company had revenue of $0.38 million during the quarter, compared to the consensus estimate of $1.33 million. On average, sell-side analysts anticipate that Syros Pharmaceuticals Inc will post -1.85 EPS for the current year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Story: Asset Allocation, Balancing Your Investments

Institutional Ownership by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply